BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...checkpoint kinase 1 (CHECK1) HER2 - Epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu) HpV16gp1...
BioCentury | Mar 27, 2019
Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

...professor of materials science and engineering and of biological engineering at MIT. Targets: E6 transforming protein (Human papillomavirus-16) - HpV16gp1...
...transforming protein (Human papillomavirus-16) - HpV16gp2; KRAS - K-Ras Mary Romeo, Staff Writer Massachusetts Institute of Technology E6 transforming protein (Human papillomavirus-16) (HpV16gp1) E7...
BioCentury | Jan 4, 2019
Financial News

Cellid proposes Korean IPO

...lead product is BVAC-C, a B cell vaccine based on E6 transforming protein (human papillomavirus-16; HpV16gp1...
...cancer. Samsung Securities is underwriting the IPO. Cellid Co. Ltd., Seoul, South Korea Chris Lieu BVAC-C Cellid Inc. E6 transforming protein (Human papillomavirus-16) (HpV16gp1) E7...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Cancer; infectious disease

INDICATION: Cancer; melanoma; cervical cancer; influenza virus Mouse and monkey studies suggest simvastatin could be used as an adjuvant to boost the efficacy of cancer and influenza vaccines. In mice, immunization with the antigen ovalbumin...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; lung cancer; ovarian cancer Patient sample, cell culture and mouse studies suggest promoting ATP5H expression or inhibiting reactive oxygen species (ROS) could help treat therapy-resistant cancers. In tumor samples from patients with...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

...cancer. ISA Pharmaceuticals B.V. has HPV-SLP, an immunotherapeutic consisting of four synthetic long peptides from HpV16gp1...
BioCentury | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

Advaxis Inc. (NASDAQ:ADXS) said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab...
BioCentury | Jul 13, 2018
Clinical News

Advaxis rises after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) jumped $0.12 (10%) to $1.34 Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the...
BioCentury | Jun 8, 2018
Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a...
Items per page:
1 - 10 of 71